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Abstract
Background: Adrenaline is the primary drug of choice for resuscitation from out-of-hospital cardiac arrest (OHCA). Although adrenaline may increase
the chance of achieving return of spontaneous circulation (ROSC), there is limited evidence that repeated doses of adrenaline improves overall survival,
and increasing evidence of a detrimental effect on neurological function in survivors. This paper reports the relationship between repeated doses of
adrenaline and survival in a cohort of patients attended by the London Ambulance Service in the United Kingdom.
Methods: A retrospective review of OHCA treated by the London Ambulance Service over a one year period. Patients aged 18 years who received one
or more doses of adrenaline (1 mg bolus) during resuscitation were included in the analyses. Outcomes described are survival to hospital discharge and
survival to one year post-arrest.
Results: Over the one year study period, 3151 patients received adrenaline during OHCA. A significant inverse relationship was found between increasing
cumulativedosesofadrenalineandsurvivalbothtohospitaldischargeandoneyearpost-arrest.Nopatientssurvivedafterreceivingmorethantenadrenalinedoses.
Conclusion: Our study indicates that repeated doses of adrenaline are associated with decreasing odds of survival. There were no survivors amongst
patients requiring more than 10 doses of adrenaline.
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Introduction
The administration of adrenaline has been the cornerstone of
treatment for out-of-hospital cardiac arrest (OHCA) for decades.1
Resuscitation guidelines worldwide recommend the use of adrena-
line, administered every 3–5 min, as part of advanced life support for
cardiac arrest from all causes and all rhythms.2–5
Evidence for a short-term beneficial effect of adrenaline in
achieving return of spontaneous circulation (ROSC) after an OHCA
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has been reported in several observational studies and meta-
analyses.6–11 Notably, the recent randomised, double-blind
PARAMEDIC2 trial, conducted within ambulance services in the
United Kingdom (UK), found a higher rate of ROSC, with a small
increase in survival to hospital discharge (<1%),12 something
supported by two previous randomised studies.13,14
Irrespective of any effect on survival, concern about the use of
adrenaline in OHCA has been growing, with accumulating evidence
indicating that its use may be harmful, particularly in terms of poorer
neurological functioning.7,9,15–17
There are also questions around the quantities and numbers of
doses of adrenaline given. One French study reported no difference in
survival between repeated administrations of high-dose (5 mg)
adrenaline and standard-dose (1 mg) adrenaline,18 while reporting
a slight increase in ROSC in the high-dose group. Another study from
America reported higher rates of survival with less frequent
administration of adrenaline than the recommended 3–5 min frequen-
cy of administration, indirectly suggesting that larger amounts of
adrenaline may have poorer outcome.
Our study sought to examine the relationship between repeated
(1 mg) doses of adrenaline and survival, and explore whether there is a
point during OHCA after which the administration of further doses, as
currently recommended, becomes futile.
Methods
Study design
A retrospective, observational analysis using anonymised data from
the London Ambulance Service (LAS) cardiac arrest registry over a
one-year period (1st April 2012 to 31st March 2013). Ethical approval
was not required as this study used data routinely collected for clinical
audit purposes.
Patient population
All adult patients (18 years of age) who experienced an OHCA of
presumed cardiac aetiology, and received one or more doses of
adrenaline (1 mg bolus) during resuscitation, were eligible for
inclusion in this study.
Study setting
The LAS covers the geographical area of Greater London, UK, which
spans approximately 620 square miles and serves a population of
8.4 million people.19 During the study period, more than 1 million
incidents were attended by the LAS,20 with over 10,000 of these being
OHCA.21
Calls identified as ‘cardiac arrest’ (using the advanced Medical
Priority Dispatch System) receive the highest level response, with a
minimum of two emergency vehicles, staffed by at least one
paramedic (trained in advanced life support), being dispatched to
the incident.
All LAS clinicians operate to the Resuscitation Council (UK)
guidelines,2 which advise the administration of adrenaline (intrave-
nous or intraosseous) for all initial rhythms during an OHCA. If the
patient presents in ventricular fibrillation or pulseless ventricular
tachycardia (VF/pVT), a 1 mg bolus of adrenaline is administered after
3 unsuccessful defibrillation attempts, whereas for non-shockable
rhythms (pulseless electrical activity (PEA) or asystole) a 1 mg bolus
of adrenaline is administered as soon as possible. If the cardiac arrest
persists, a further dose of adrenaline is advised every 3–5 min with no
upper dose limit until either ROSC is achieved and the patient is
handed over to hospital, or the resuscitation attempt is terminated. If
ROSC is achieved, local LAS protocol allows a lower dose of
adrenaline (0.1 mg bolus) to be administered to maintain the patient’s
blood pressure and prevent re-arrest.
Data collection
Data were obtained from the LAS Out-of-Hospital Cardiac Arrest
Registry that collates patient, process, treatment and outcome
information from multiple sources (including emergency dispatch call
logs, and ambulance service and hospital clinical patient records) to
provide a comprehensive clinical record for each OHCA. Character-
istics and outcomes recorded include: patient demographics, location
of arrest, presenting cardiac rhythm, bystander intervention, pre-
hospital resuscitation methods, ROSC and survival to hospital
discharge. Long-term outcome, with survival up to 1 year post-arrest,
was obtained from NHS Digital Summary Care Records.
Data analysis
Data analysis and statistics were performed using Excel (Microsoft,
Redmond, WA), SPSS v23 (IBM, Armonk, NY) and R 3.5.1 (A
Language and Environment for Statistical Computing). Statistical
significance was accepted when p < 0.05.
The association between percentage survival (to hospital
discharge and to one year post-arrest) and independent explanatory
variables was assessed using a step-wise multivariate logistic
regression model. We first undertook univariate logistic regressions
on all known predictors of survival (age, sex, adrenaline dose group,
initial shockable rhythm, time from EMS call to first adrenaline dose,
ROSC, bystander CPR, and witness status). We then built a step-wise
multivariate regression model starting with the predictor that had the
strongest association with the outcome based on the partial F-tests
obtained from the regression. At each step we added the predictor that
had the next strongest association or excluded the predictor that no
longer explained the outcome. We stopped this procedure when no
more predictors could be added or removed, and this is the final model
upon which the results are based. Collinearity between the predictors
was assessed by calculating the variance inflation factor (VIF) for each
predictor and excluding those variables that had a VIF greater than 5.
No predictor met this criterion and therefore none were removed from
analysis based on collinearity. The number of doses of adrenaline
were categorised into three categories, 1 dose, 2 doses, and >3 doses
in the multivariate analysis.
When presenting results, continuous variables are presented as
means  standard deviation (SD) and categorical variables are reported
as counts with relative frequencies. Adjusted odds ratios (AOR) and 95%
confidence intervals (CI)obtainedfrom the multi-variable binomial logistic
regression after controlling for potential confounders were used to
interpret associations between variables and outcomes.
Results
Resuscitation was attempted for 4466 OHCA patients; with 3151 (71%)
meeting the criteria for inclusion in the study (see Fig. 1). In total, 137
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(4.3%) patients survived to be discharged from hospital, with 108 of
122 patients (88.5%; with 15 lost to follow up) still alive at one year
(representing 3.4% overall). Patient demographics and key event
characteristics based on patient outcome are summarised in Table 1.
Compared to non-survivors, those who survived to one year had almost
four fewer doses of adrenaline on average (p < 0.001), presented with
an initial shockable rhythm (VF/VT) (p < 0.0001), were more likely to
have had a witnessed arrest (p < 0.001), received a higher number of
shocks (p < 0.001) and had an ‘EMS call’ to ‘administration of first
adrenaline dose’ interval that averaged 5 min faster (p < 0.001).
Each 1 min of delay from ‘EMS’ call to ‘administration of first
adrenaline dose’ was associated with a 7% reduction in survival
(OR = 0.93; CI = 0.91, 0.96; p < 0.0001) to both hospital discharge and
one year post arrest. However, this association was no longer
significant after adjusting for other covariates in the multivariate
regression model (AOR = 0.98; CI = 0.95, 1.00; p = 0.09).
Association of repeated doses of adrenaline and survival
The relationship between repeated adrenaline doses and survival
both to hospital discharge and to one year post-arrest is presented in
Fig. 2 and Supplementary Table 1. The number of adrenaline doses
administered had a negative association with both measures of
survival. Survival to hospital discharge was approximately 20% with
one dose of adrenaline, rapidly declining to less than 2% at five or
more doses. Survival to one year followed a similar pattern. There
were no survivors amongst patients who received more than 10 doses
of adrenaline.
While there were variables listed in Table 1 that were significantly
associated with survival at the univariate level, only adrenaline dose
group, presence of an initial shockable rhythm, age and sex could
significantly predict survival in the step-wise regression model.
Therefore we present association of adrenaline dose group with
survival after adjusting for the significant confounders, initial
shockable rhythm, age and sex.
Multivariate analysis revealed that when adjusted for the effects of
age, sex, and an initial shockable rhythm, three or more doses of
adrenaline were associated with an 85% decrease in the likelihood of
surviving to hospital discharge (AOR = 0.15; CI = 0.09, 0.26; p
< 0.0001) and an 82% decrease in surviving to one year (AOR =
0.18; CI = 0.1, 0.11; p < 0.0001). Full analysis results are detailed in
Table 2.
Two patients (out of 190; 1.1%) who received 9 doses of
adrenaline, and a further 2 patients (out of 224; 0.9%) who received
Fig. 1 – Overview of cases meeting our inclusion criteria and outcomes.
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exactly 10 doses of adrenaline, survived to hospital discharge and
were still alive at one year (see Supplementary Table 2 for details of
these patients). The first dose of adrenaline was administered to all
four patients in less than 13 min from initiation of CPR, well within the
overall average (15 min). All cases had an end-tidal carbon dioxide
(ETCO2) value over 20 mmHg with Cases 1 and 3 exceeding
30 mmHg. Case 2, 3 and 4 had intermittent ROSC during resuscita-
tion, with Cases 1, 2 and 3 achieving a stable ROSC which was
sustained from the arrest location to hospital handover. In addition, the
three patients who suffered a myocardial infarction (Cases 1, 2 and 4)
were conveyed by ambulance directly to a specialist heart attack
centre for coronary intervention.
Table 1 – Patient demographics and key event characteristics for out-of-hospital cardiac arrests (OHCA) where one
or more dose of adrenaline (1 mg) was administered during resuscitation. Univariate analysis was used to compare
patients who survived to 1 year and those who died. 33 cases were excluded from analysis due to unknown
outcomes. SD, standard deviation; CPR, cardiopulmonary resuscitation; EMS, emergency medical service; VF,
ventricular fibrillation; pVT, pulseless ventricular tachycardia; PEA, pulseless electrical activity.
Characteristics Outcome at hospital discharge Outcome at one-year
Survived
n = 137
Died
n = 2997
p-value Survived
n = 108
Died
n = 3011
p-value
Age (years), mean  SD 57.7  15.4 70.4  16.8 <0.001 57.1  15.3 70.4  16.8 <0.001
Sex (male), n (%) 118 (86.1) 1821 (60.8) <0.001 92 (85.2) 1834 (60.9) <0.001
Witnessed arrest, n (%) 112 (81.8) 1879 (62.7) <0.001 87 (80.6) 1891 (62.8) <0.001
Bystander 89 (65.0) 1445 (48.2) 68 (63.0) 1455 (48.3)
EMS clinician 23 (16.8) 434 (14.5) 19 (17.6) 436 (14.5)
Not witnessed 25 (18.2) 1116 (37.2) 21 (19.4) 1118 (37.1)
Bystander CPR, n (%) 65 (47.4) 1277 (42.6) 0.263 51 (47.2) 1282 (42.6) 0.338
Defibrillation performed, n (%)
Pre-EMS defibrillation 3 (2.2) 25 (0.8) 0.099 1 (0.9) 26 (0.9) 0.945
EMS defibrillation 108 (78.8) 991 (33.1) <0.001 94 (87.0) 996 (33.1) <0.001
Number of shocks, mean  SD 3.5  3.1 1.7  3.7 <0.001 3.9  3.1 1.7  3.4 <0.001
Initial arrest rhythm, n (%)
Asystole 18 (13.1) 1671 (55.8) <0.001 9 (8.3) 1678 (55.7) <0.001
VF/pVT 101 (73.7) 520 (17.4) 88 (81.5) 524 (17.4)
PEA 17 (12.4) 802 (26.8) 10 (9.3) 805 (26.7)
Unknown 1 (0.7) 4 (0.1) 1 (0.9) 4 (0.1)
Successful intubation, n (%) 49 (35.8) 1241 (41.4) 0.108 34 (31.5) 1251 (41.5) 0.036
Dose of adrenaline, Mean  SD 2.6  1.9 6.2  3.4 <0.001 2.6  1.9 6.2  3.4 <0.001
Time from EMS call to first Adrenaline dose (MM:SS), Mean  SD 21:39  11:0 26:5113:3 <0.001 21:08  10:4 26:39  13:3 <0.001
Fig. 2 – Relationship between the number of adrenaline doses and percentage survival to hospital discharge and
survival to 1-year post-arrest. Shaded regions represent 95% confidence interval. 33 unknown outcomes were
excluded from analysis.
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A total of 267 patients received more than 10 doses of adrenaline,
and none survived. Using the ‘rule of three’22 our study predicts that
more than 10 doses of adrenaline will result in no more than 1.1%
(95% CI 0–1.1) of patients surviving to hospital discharge and one year
post arrest.
Discussion
This study sought to describe the association between repeated
doses of adrenaline and survival. We found that three or more doses
were associated with a significant reduction in the odds of surviving to
both hospital discharge and to one year post-arrest. The decline in
survival was evident up to five cumulative doses of adrenaline, at
which point the relationship flattened due to very few survivors, with no
survivors after ten doses. The significant inverse relationship between
cumulative doses of adrenaline and survival persisted even after
adjusting for potential confounders using multivariate analysis.
These results support the findings of Glover et al.23 who described
an independentnegative association between the probability of survival
to hospital discharge and adrenaline dose in the US and Canada. We
found four patients who, despite a higher number of adrenaline doses
(9 or 10 doses), were still alive one year post-arrest. However, it is likely
that the favourable factors observed (which included a reversible cause
of arrest, conveyance to a specialist centre, and a short time to first
adrenaline dose) contributed to their survival.
While in our study, ‘EMS call’ to ‘administration of first adrenaline
dose’ interval was not significantly associated with survival after
adjusting for confounders, previous studies have identified a
relationship between time to first dose of adrenaline and surviv-
al24–28 in their multivariate models. Hubble et al observed a 4%
reduction in the odds of obtaining ROSC for every one minute delay
from emergency call to administration of a vasopressor.24 Two other
studies suggested that, when administered within 20 min of the
emergency call, repeated doses of adrenaline were associated with
improved neurological outcome for witnessed cardiogenic OH-
CA.25,26 Hayashi et al further demonstrated that for patients in VF/
VT,27 administration of adrenaline within 10 min of the emergency
call was associated with better one-month neurological outcome.28
In our study, those who survived to one year had an ‘EMS call’ to
‘first adrenaline dose’ time interval that was, on average, five
minutes faster compared to those who died. It is to be noted
however, that variables used to build multivariate models differed in
all these studies and perhaps could explain the difference in results.
Beinganobservationalstudy,wewereunable toseparate theeffectof
the number of adrenaline doses, from the length of time a patient was in
cardiac arrest and the severity of their condition, both of which are known
to influence outcome.29 As such, our findings must be interpreted with
caution. It is likely that cumulative doses of adrenaline are a proxy for
cardiac arrest duration, which is associated with increasingly poor
outcome,aphenomenonthathasbeentermed ‘resuscitationtimebias’.29
However, given that adrenaline increases the likelihood of achieving
ROSC, these two variables are heavily interdependent. The observed
effects may also be attributed to other unknown confounders.
There are further limitations in the data available for our study. We
were unable to obtain neurological outcomes from hospitals, and this
would have provided a valuable insight into the neurological effects of
cumulative adrenaline doses and the quality of life for OHCA
survivors. Technological limitations within our EMS system prevented
defibrillator downloads from being available for analysis; these data
would have enabled us to assess the quality of CPR, something which
may have impacted on drug delivery and subsequent efficacy.30
Despite the limitations, our findings support the need for further
research into the efficacy, timing and dosage of adrenaline during
resuscitation. Current guidelines recommend administration of
adrenaline (1 mg) every 3–5 min2; however, in-hospital studies
suggest that a less frequent dosing strategy may increase survival31
and could reduce development of secondary VF/VT.32 One study
comparing high-dose adrenaline (15 mg) with the standard dose
(1 mg), documented an increase in ROSC and survival to hospital
admission with the higher dose.33 In contrast, Frisk et al. investigated
a lower adrenaline dose (0.5 mg), which did not affect survival to
hospital discharge or favourable neurological outcome for OHCA
patients.34 It is clear that the optimum dose of adrenaline is a
knowledge gap that needs further investigation.35
Conclusion
Our study indicates that repeated doses of adrenaline are associated
with decreasing odds of survival. There were no survivors amongst
patients requiring more than 10 doses of adrenaline.
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Table 2 – Adjusted odds ratios (AOR) for survival to
hospital discharge and 1 year post-arrest.
Multivariate analysis was used to control for potential
confounders listed on Table 1.
AOR (95% CI)a p-value
Outcome at hospital discharge
1 dose of adrenaline Reference (–)
2 doses of adrenaline 0.7 (0.39, 1.28) 0.67
3 doses of adrenaline 0.15 (0.09, 0.26) <0.0001
Initial shockable rhythm (not present) Reference (–)
Initial shockable rhythm (present) 9.83 (6.1, 15.86) <0.0001
Age 0.96 (0.95, 0.97) <0.0001
Sex (Male) Reference (–)
Sex (Female) 2.98 (1.66, 5.33) 0.0002
Outcome at 1 year
1 dose of adrenaline Reference (–)
2 doses of adrenaline 0.85 (0.46, 1.62) 0.62
3 doses of adrenaline 0.18 (0.1, 0.33) <0.0001
Initial shockable rhythm (not present) Reference (–)
Initial shockable rhythm (present) 14.27 (8.26, 24.6) <0.0001
Age 0.96 (0.95, 0.98) <0.0001
Sex (Male) Reference (–)
Sex (Female) 2.49 (1.36, 4.58) 0.003
SD, standard deviation; CI, confidence interval.
a An adjusted odds ratio above 1.0 favors survival.
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Appendix A. Supplementary data
Supplementary material related to this article can be found, in the online
version, at doi:https://doi.org/10.1016/j.resuscitation.2019.01.022.
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